Cytori Licenses Asia-Pacific Cardiovascular, Renal & Diabetes Markets to Lorem Vascular for up to $531 Million

  Cytori Licenses Asia-Pacific Cardiovascular, Renal & Diabetes Markets to
  Lorem Vascular for up to $531 Million

     Cytori to Receive $31 Million Upfront in Equity and Initial Purchase

Business Wire


Cytori Therapeutics (NASDAQ: CYTX) and Lorem Vascular today announced a
partnership to commercialize Cytori Cell Therapy for the cardiovascular, renal
and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia.
Under the agreement, Lorem Vascular committed to pay up to $531 million in
license fees, opening product purchase commitments and Cytori equity
purchases. Cytori Cell Therapy is derived from the Company’s Celution® System,
which enables access to a patient’s own adipose-derived regenerative cells
(ADRCs) at the point-of-care.

Lorem Vascular will pay up to $500 million in fees for a 30-year exclusive
license to Cytori Cell Therapy for all indications, excepting alopecia and
aesthetics, in the licensed territories in the form of revenue milestones. In
addition, Lorem Vascular agrees to purchase the Cytori Celution® System and
consumables under a product supply agreement. Cytori will receive $24 million
in exchange for 8 million shares of Cytori common stock at $3.00 per share.
Equity purchased will be closed in two installments; a $12 million payment
that will be paid within 7 days and a second $12 million payment that will be
made within 60 days. In addition, Lorem Vascular will order $7 million in
Celution® devices and consumables with a $2 million order placed immediately
and a $5 million order to be placed following regulatory approval in China.
Lorem and Cytori have implemented a regulatory plan in China and anticipate
approval in 2014. One board seat will be granted to Mr. K.T. Lim, Chairman of
Lorem Vascular.

“Cytori Cell Therapy will transform the way healthcare addresses the most
costly and insidious diseases impacting healthcare today and well into the
future,” said Mr. K.T. Lim. “This therapy represents a front-line treatment
modality that will serve as the centerpiece of our cardiovascular, renal and
diabetes commercial activities across the region. Lorem Vascular will initiate
an immediate launch in Hong Kong, Singapore and Australia. A subsequent launch
in China and Malaysia is planned in 2014, pending regulatory approvals.”

“Through this agreement with Lorem Vascular, we have secured a committed
partner to bring Cytori Cell Therapy to patients in countries where we have
recently received, or are in the process of achieving, regulatory approval,”
said Christopher J. Calhoun, Chief Executive Officer of Cytori. “With the
Celution® System now approved and available in more than 40 countries, we are
uniquely positioned to expand our cell therapy brand by being first-to-market
with cell therapy products in new geographies around the world. Lorem Vascular
brings to Cytori the required resources, market knowledge, dedication and
focus to commercialize this innovative treatment and pioneer the introduction
of cell therapy products for patients with the most serious conditions.”

More than 230 million Chinese have a form of Cardiovascular Disease (CVD)
which is the country’s leading cause of death, accounting for more than 40% of
all deaths, or three million people per year. This translates to one death
every ten seconds from CVD in China. According to recent estimates, due to
population growth and aging, the number of annual CVD events in China is
projected to increase by more than 50% during the next decade and a half. The
growing worldwide prevalence of diabetes is one of the contributing factors to
increasing rates of vascular diseases, as they are common co-morbidities of

“Expanding in emerging markets throughout the world is critical to our mission
and growth and partnerships such as this are a key driver of our approach,”
said David Oxley, Vice President for Emerging Markets at Cytori. “China is one
of the three largest and highest value medical markets in the world. A market
penetration of less than 5% of the cardiovascular market alone represents
millions of patients treated in the next thirty years, a multiple of billions
in cost savings to the People’s Republic of China, and a transformation in the
quality and standard of care. Today’s announcement with Lorem Vascular marks
the beginning of an important partnership in transforming healthcare and will
create long-term shareholder value.”

About Cytori Cell Therapy and the Celution® System

Cytori Cell Therapy is derived from the Company’s Celution® System, an
innovative and proprietary medical device that enables access to a patient’s
own adipose (fat tissue)-derived regenerative cells at the point-of-care for a
range of injuries and conditions. Adipose tissue is considered the richest
source of regenerative cells in the body. These cells are comprised of a
heterogeneous population of cells, which are collectively referred to as
ADRCs. The heterogeneous nature of Cytori Cell Therapy and ADRCs are believed
to contribute to the healing process via multiple mechanisms, which include
cell-to-cell signaling, supporting improved blood flow and regulation of the
inflammatory response.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
other medical conditions. Our scientific data suggest ADRCs improve blood
flow, moderate the inflammatory response and keep tissue at risk of dying
alive. As a result, we believe these cells can be applied across multiple
“ischemic” conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori’s proprietary technologies and
products, including the Celution System product family.

About Lorem Vascular

Lorem Vascular will be a leader in cardiovascular care with world-class
regenerative medicine therapy. Headquartered in Beijing, with offices in Hong
Kong, Kuala Lumpur, Singapore, and Melbourne, Lorem Vascular is committed to
advancing patient care by transforming the treatment of cardiovascular disease
by providing access to innovative medical technology to facilitate
regenerative medicine, hospital and physician training and continuing medical
education. The Company offers a cutting-edge regenerative medicine platform
for treating such things as peripheral vascular disease, acute myocardial
infarction and chronic heart disease. Our flagship platform is the
market-leading Celution® System developed by Cytori Therapeutics (USA).

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating results
and financial position. Such statements, including, but not limited to, those
regarding our ability to obtain regulatory approvals in China and other
countries in the specified timeframe, and Lorem Vascular’s ability to
successfully launch the Celution® platform in China, Hong Kong, Malaysia,
Singapore and Australia in the timeframes indicated are subject to risks and
uncertainties that could cause our actual results and financial position to
differ materially. Some of these risks and uncertainties include the
challenges inherent in Lorem Vascular convincing physicians and patients to
adopt the new technology, regulatory uncertainties, dependence on third party
performance, and other risks and uncertainties described under the "Risk
Factors" section in Cytori's Securities and Exchange Commission Filings on
Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise
any forward-looking statements contained in this press release to reflect
events, trends or circumstances after the date of this press release.


Cytori Therapeutics
Investor Relations
Tom Baker
Megan McCormick
Linnden Communications
Michelle Linn
+1-508-362-3087 or +1-774-696-3803
Press spacebar to pause and continue. Press esc to stop.